Home / Science / Owkin AI Powers Servier's Oncology Breakthroughs
Owkin AI Powers Servier's Oncology Breakthroughs
11 Sep
Summary
- Owkin's AI scientist, K Pro, licensed to Servier.
- Multimodal patient data from Owkin's MOSAIC network accessible.
- Focus on advancing oncology research and hard-to-treat cancers.
Owkin announced a significant agreement with Servier, a global pharmaceutical group. Under this deal, Servier will license Owkin's AI scientist, K Pro, and utilize multimodal patient data to advance its oncology research efforts. This partnership marks a new phase in their ongoing collaboration.
Servier's research teams will gain access to Owkin's MOSAIC network data through K Pro. This AI scientist is designed to expedite drug discovery and development by analyzing complex biological data. It aids in areas such as molecule optimization, target discovery, and clinical trial design.
Owkin's CEO, Thomas Clozel, highlighted that their AI scientist is transforming biopharma. By integrating K Pro with patient data, Servier scientists can delve deeper into the biology of challenging cancers. This capability is expected to yield insights unattainable through manual analysis alone.
Claude Bertrand of Servier emphasized the value of this collaboration. Access to high-quality patient data and AI-driven analysis within K Pro will empower Servier's teams to generate and test hypotheses more rapidly and confidently. This will be applied across their oncology research programs.
